A phase III randomized controlled trial of anastrozole compared to anastrozole plus fulvestrant as adjuvant endocrine therapy for postmenopausal women with estrogen receptor +/- progesterone receptor positive breast cancer

Trial Profile

A phase III randomized controlled trial of anastrozole compared to anastrozole plus fulvestrant as adjuvant endocrine therapy for postmenopausal women with estrogen receptor +/- progesterone receptor positive breast cancer

Planning
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2008

At a glance

  • Drugs Anastrozole (Primary) ; Fulvestrant (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Dec 2008 Last checked against National Cancer Institute of Canada record.
    • 04 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top